(Q33813199)

29 July 2017

0 references

1 reference

title

Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials (English)

1 reference

29 July 2017

1 reference

1 reference

P Schoenfeld

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

American Journal of Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

107

1 reference

29 July 2017

issue

6A

1 reference

29 July 2017

page(s)

48S-54S

1 reference

Meloxicam: selective COX-2 inhibition in clinical practice

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Safety of meloxicam: a global analysis of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Meta-analysis: State-of-the-Science

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

The existence of publication bias and risk factors for its occurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900367-8

10.1016/S0002-9343(99)00367-8

7 January 2021

Identifiers

DOI

1 reference

release_vnnfqny6kjferdamhnzaggqrcq

29 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vnnfqny6kjferdamhnzaggqrcq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference